SecBot SecBot
Biotech Drug Report Generated Nov 19, 2026

KIMYRSA

CRMD·CorMedix Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available since 2021. Currently marketed by CorMedix following the Melinta acquisition.
Why 4/10
KIMYRSA is already FDA-approved and commercially launched with no pending regulatory decision. The next hard catalyst for CorMedix is the REZZAYO sNDA PDUFA decision in Q1 2027, not specific to KIMYRSA. As one of several marketed products in a diversified portfolio, KIMYRSA alone does not drive a binary share-price move.
Actionable Insight NEUTRAL

KIMYRSA is an already-approved, commercial-stage asset within CorMedix's broader portfolio. The next major company-wide catalyst is the REZZAYO sNDA PDUFA decision in Q1 2027, not anything specific to KIMYRSA. Watch for Q4 2026 earnings (likely Feb/Mar 2027) for updates on Melinta portfolio revenue contributions including KIMYRSA, and the Heron Therapeutics acquisition closing (expected Q1 2027).

Price Chart

Loading chart...

Executive Summary

KIMYRSA (oritavancin) is an FDA-approved, single-dose IV antibiotic for acute bacterial skin and skin structure infections (ABSSSI), including MRSA. Originally developed and launched by Melinta Therapeutics in 2021, it became part of CorMedix's portfolio through the $300M acquisition of Melinta that closed in September 2025. KIMYRSA is one of seven marketed products CorMedix gained in the deal, alongside the lead product DefenCath and others like REZZAYO and MINOCIN. The drug is already commercialized with no pending regulatory catalysts, making it a steady revenue contributor within a broader, diversified portfolio. CorMedix's stock trades at ~$4.55 (down from a 52-week high of $13.02) with strong analyst support (mean price target $13.80) and recent insider buying.

How It Works

KIMYRSA (oritavancin) is a lipoglycopeptide antibiotic given as a single, one-time intravenous infusion. It works by disrupting the cell wall of certain Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Its key advantage is the single-dose regimen, which allows patients with serious skin infections to be treated with one infusion rather than multiple days of daily IV antibiotics, potentially enabling outpatient treatment or earlier hospital discharge.

Trial Status

KIMYRSA was FDA-approved in March 2021 based on clinical trials demonstrating efficacy in ABSSSI. It is a fully commercialized product. No new clinical trials for KIMYRSA are being conducted by CorMedix.

The Two-Sided Case

▲ Bull Case4
KIMYRSA is an FDA-approved, commercially launched product with a differentiated profile: a single-dose, long-acting IV lipoglycopeptide antibiotic for ABSSSI (including MRSA), offering convenience over multi-dose regimens.
CorMedix acquired KIMYRSA via the $300M Melinta Therapeutics acquisition (closed September 2025), adding seven marketed drugs that diversify revenue beyond the lead product DefenCath and provide cross-selling opportunities in acute-care settings.
Analyst consensus is strongly bullish: 11 Buy/Strong Buy ratings vs 1 Hold, with a mean price target of $13.80 (205% upside from ~$4.55). Recent insider buying by the CEO ($391K) and a director ($122K) at ~$4.88-4.89 signals confidence.
Institutional accumulation is strong: American Century doubled its position, Goldman Sachs doubled, and JPMorgan nearly tripled their stakes in Q3 2026.
▼ Bear Case4
KIMYRSA faces competition from other oritavancin products like Orbactiv (also oritavancin) and other ABSSSI antibiotics such as dalbavancin and telavancin.
As a single product within a larger portfolio acquired via Melinta ($300M deal), KIMYRSA's individual contribution to CorMedix's revenue is not separately disclosed, making it hard to assess its standalone performance.
CorMedix's stock has fallen sharply from its 52-week high of $13.02 to ~$4.55, reflecting market concerns about DefenCath's post-TDAPA revenue decline and execution risk across the combined portfolio.
The broader antibiotic market faces pricing and reimbursement headwinds, and KIMYRSA as a hospital-administered product is subject to institutional contracting dynamics.

Upcoming Catalysts

  • REZZAYO sNDA PDUFA decision (Q1 2027) - the next major binary catalyst for CorMedix
  • Heron Therapeutics asset acquisition closing (expected Q1 2027)
  • Q4 2026 and full-year 2026 earnings report (expected Feb/Mar 2027) - will show Melinta portfolio revenue including KIMYRSA contribution

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CorMedix Inc. DEFA14A CRMD ·Originating report

Sources · 7

Hover a chip for the title
1 businesswire.com2 raps.org3 empr.com4 businesswire.com5 fiercepharma.com6 seekingalpha.com7 marketscreener.com